On Monday, BofA Securities analyst Greg Harrison upgraded United Therapeutics Corporation (NASDAQ:UTHR) from Underperform to Neutral, setting a price target of $314.00 for the company’s shares.

On Monday, BofA Securities analyst Greg Harrison upgraded United Therapeutics Corporation (NASDAQ:UTHR) from Underperform to Neutral, setting a price target of $314.00 for the company’s shares.

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

Roche will invest $50 billion in U.S. manufacturing, including a new plant in Indiana. The Trump administration is ...

The hardware segment of AI in the manufacturing market in the US is set to experience substantial growth, driven by the increasing demand for high-performance processors that can efficiently ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 16, 2025--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results ...

Adopting a "strategic infill development and vertical expansion" approach, the design retains well-preserved existing buildings, and respects the original campus layout while introducing modern ...

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing ...

Suite Awards. The San Antonio Business Journal is seeking nominations for its 2025 C-Suite Awards, which will honor ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...